| |
Leadership
Senior Management Team
Jeffrey L. Cleland, Ph.D.
Chief Executive Officer, Founder
Jeff has 20 years of industry experience in research and development, including more than a decade at Genentech, Inc. He held executive management positions at BaroFold, Novacea, and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. His experience in start-ups includes major roles in obtaining more than $70M of Series A through C venture capital as well as an exit via IPO. Jeff also runs his own pharmaceutical and biotechnology consulting group for numerous start-ups and venture firms. While at Genentech, Jeff served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as early work on Lucentis®, Avastin®, and Omnitarg®. He holds a BS degree in Chemical Engineering from the University of California, Davis and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Jeff has authored more than 100 articles and four books, and holds several issued patents.
Paul Westberg
Senior Vice President, Business Development
Paul joined Versartis from Bayhill Therapeutics, where he was the Vice President of Business Development, responsible for the company’s licensing activities and a key contributor to its fundraising and operational activities. Most notably, Paul recently led and closed a transformational $350M+ licensing deal with Genentech for its novel Phase I/II program in type 1 diabetes. Prior to Bayhill, Paul was the Vice President of Business Development at Novacea, where he was responsible for closing multiple transactions including the licensing of two clinical-stage products. In addition, he was a key contributor to Novacea’s fundraising efforts, which resulted in approximately $100M in private equity financing and a successful IPO. Previously, Paul held managerial positions at Deltagen, Collabra Pharma and Aviron, where he was responsible for establishing transactional, business development and financial planning operations, respectively. Earlier, Paul held positions of increasing responsibility at Genentech, including Manager, Project Finance and Manager, Financial Planning and Analysis. He began his career advising clients on product and company valuation, technology assessment, and commercialization issues. Paul holds an MBA from the Haas School of Business at the University of California, Berkeley and BA in Applied Mathematics from the University of California, San Diego.
|
|
| |
|
|
